Curis Inc. (CRIS)

2.36
0.47 16.61
NASDAQ : Health Technology
Prev Close 2.83
Open 2.80
Day Low/High 2.35 / 2.90
52 Wk Low/High 0.60 / 2.85
Volume 942.32K
Avg Volume 131.80K
Exchange NASDAQ
Shares Outstanding 33.15M
Market Cap 81.55M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

CRIS: Insiders Vs. Shorts

CRIS: Insiders Vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 10/15/2013 settlement date, and Curis Inc is one of the most shorted stocks of the Russell 3000, based on 5.44 "days to cover" versus the median component at 4.95. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Interesting CRIS Put And Call Options For June 2014

Interesting CRIS Put And Call Options For June 2014

Investors in Curis Inc saw new options become available this week, for the June 2014 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 222 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Curis And Debiopharm Group(TM) Announce Initiation Of Phase I Dose Finding Clinical Study With A Combination Of HSP90 Inhibitor Debio 0932 And Everolimus (Afinitor)(R)

Curis And Debiopharm Group(TM) Announce Initiation Of Phase I Dose Finding Clinical Study With A Combination Of HSP90 Inhibitor Debio 0932 And Everolimus (Afinitor)(R)

- Designed to Target Advanced Metastatic Renal Cell Carcinoma, the Study Will Determine the Maximum Tolerated Dose of Debio 0932 in Combination With Everolimus -

Curis Announces Initiation Of A Roche-Sponsored Phase 1b/2 Study Of Erivedge(R) (vismodegib) In Relapsed/Refractory AML And High Risk MDS

Curis Announces Initiation Of A Roche-Sponsored Phase 1b/2 Study Of Erivedge(R) (vismodegib) In Relapsed/Refractory AML And High Risk MDS

AML and MDS Represent Non-Mutation Driven Hedgehog Pathway Malignancies

Dealing With the Shutdown Maze

The D. C. childishness could undermine consumer confidence.

Commit To Purchase Curis At $2.50, Earn 8.5% Annualized

Commit To Purchase Curis At $2.50, Earn 8.5% Annualized

Investors considering a purchase of Curis shares, but tentative about paying the going market price of $4.64/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2014 put at the $2.50 strike, which has a bid at the time of this writing of 10 cents.

Curis Strengthens Leadership Team With Appointments Of Jaye Viner, M.D. As Chief Medical Officer And Tania Chander, Pharm.D. As VP Of Product Development

Curis Strengthens Leadership Team With Appointments Of Jaye Viner, M.D. As Chief Medical Officer And Tania Chander, Pharm.D. As VP Of Product Development

Dr. Viner Brings Significant Drug Development and Molecular Oncology Expertise

Curis Reports Second Quarter 2013 Financial Results

Curis Reports Second Quarter 2013 Financial Results

Management to Host Conference Call Today at 9:00 a.m. EDT

13 Stocks Under $10 Setting up to Spike Higher

13 Stocks Under $10 Setting up to Spike Higher

These under-$10 stocks look poised to trade higher from current levels.

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Keep these health care stocks under $10 on your radar.

Curis Announces Initiation Of A Clinical Trial Of CUDC-427 In Advanced Malignancies

Curis Announces Initiation Of A Clinical Trial Of CUDC-427 In Advanced Malignancies

Expansion Cohort Primarily to Include Ovarian and Fallopian Tube Cancers

Curis Announces The Conditional Approval Of Erivedge(R) In The European Union

Curis Announces The Conditional Approval Of Erivedge(R) In The European Union

-Triggers $6 Million Milestone Payment to Curis-

Commit To Buy Curis At $2.50, Earn 12.4% Annualized

Commit To Buy Curis At $2.50, Earn 12.4% Annualized

Investors considering a purchase of Curis Inc stock, but tentative about paying the going market price of $3.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $2.50 strike, which has a bid at the time of this writing of 15 cents.

TheStreet Quant Rating: D- (Sell)